Join
Live feed
·
PRReleasevia Quantisnow
Theravance Biopharma Inc. logo

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

ByQuantisnow·Wall Street's wire, on your screen.
TBPH· Theravance Biopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TBPH (Theravance Biopharma Inc.) and more on Quantisnow.